MorphoSys (ETR:MOR) Given a €30.00 Price Target at Deutsche Bank Rese…

Deutsche Bank Rese… set a €30.00 ($31.58) price objective on MorphoSys (ETR:MORGet Rating) in a report released on Wednesday morning, Borsen Zeitung reports.

Other analysts have also issued reports about the stock. Berenberg Bank set a €65.00 ($68.42) target price on shares of MorphoSys in a research note on Thursday, March 24th. Barclays set a €36.00 ($37.89) target price on shares of MorphoSys in a research note on Thursday, March 17th. JPMorgan Chase & Co. set a €40.00 ($42.11) target price on shares of MorphoSys in a research note on Thursday, March 17th. Finally, Deutsche Bank Aktiengesellschaft set a €30.00 ($31.58) target price on shares of MorphoSys in a research note on Tuesday, March 22nd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Buy and an average target price of €52.00 ($54.74).

MOR stock opened at €19.46 ($20.48) on Wednesday. The company has a quick ratio of 3.79, a current ratio of 3.98 and a debt-to-equity ratio of 133.04. MorphoSys has a twelve month low of €20.76 ($21.85) and a twelve month high of €80.14 ($84.36). The stock has a market capitalization of $664.54 million and a price-to-earnings ratio of -1.32. The firm’s fifty day simple moving average is €23.72 and its two-hundred day simple moving average is €29.80.

MorphoSys Company Profile (Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

See Also

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.